Prevalence of Multimorbidity in the Middle East: A Systematic Review of Observational Studies.
Middle East
demographics association
multimorbidity
prevalence
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
08 12 2022
08 12 2022
Historique:
received:
25
10
2022
revised:
24
11
2022
accepted:
05
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
There has not been a review that evaluated the prevalence of multimorbidity in the Middle East. This review aims to measure the prevalence, demographic factors, and consequences of multimorbidity in the Middle East region. A quantitative systematic review includes cross-sectional and longitudinal cohort studies. The prevalence systematic review approach from the Joanna Briggs Institute was applied. We searched PsychINFO, MEDLINE, EMCARE, CINAHL, Scopus, Science Direct, and the Cochrane Central Register of Controlled Trials. Data were extracted methodically in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards. Studies written in English and released between 2012 and March 2022 were included. For the meta-analysis, a random-effects model was applied. PROSPERO registration number: CRD42022335534. The final sample consisted of eight cohort and observational studies. The number of participants varied from 354 to 796,427. Multimorbidity was present in all populations with a prevalence of 21.8% (95% confidence interval (CI): 21.7-21.8%). Multimorbidity affects a significant section of the world's population. A uniform operationalization of multimorbidity is required in the Middle East in order to enable reliable estimates of illness burden, effective disease management, and resource distribution.
Sections du résumé
BACKGROUND
There has not been a review that evaluated the prevalence of multimorbidity in the Middle East. This review aims to measure the prevalence, demographic factors, and consequences of multimorbidity in the Middle East region.
STUDY DESIGN
A quantitative systematic review includes cross-sectional and longitudinal cohort studies.
METHODS
The prevalence systematic review approach from the Joanna Briggs Institute was applied. We searched PsychINFO, MEDLINE, EMCARE, CINAHL, Scopus, Science Direct, and the Cochrane Central Register of Controlled Trials. Data were extracted methodically in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards. Studies written in English and released between 2012 and March 2022 were included. For the meta-analysis, a random-effects model was applied. PROSPERO registration number: CRD42022335534.
RESULTS
The final sample consisted of eight cohort and observational studies. The number of participants varied from 354 to 796,427. Multimorbidity was present in all populations with a prevalence of 21.8% (95% confidence interval (CI): 21.7-21.8%).
CONCLUSION
Multimorbidity affects a significant section of the world's population. A uniform operationalization of multimorbidity is required in the Middle East in order to enable reliable estimates of illness burden, effective disease management, and resource distribution.
Identifiants
pubmed: 36554382
pii: ijerph192416502
doi: 10.3390/ijerph192416502
pmc: PMC9778740
pii:
doi:
Types de publication
Systematic Review
Meta-Analysis
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
J Community Health. 2020 Dec;45(6):1270-1282
pubmed: 32918645
PLoS One. 2010 Dec 29;5(12):e15941
pubmed: 21209965
BMJ Open. 2017 May 9;7(5):e013548
pubmed: 28490550
Ann Fam Med. 2012 Mar-Apr;10(2):142-51
pubmed: 22412006
Health Qual Life Outcomes. 2015 Oct 15;13:168
pubmed: 26467295
Arch Gerontol Geriatr. 2016 Nov-Dec;67:130-8
pubmed: 27500661
PLoS One. 2015 Jul 08;10(7):e0127199
pubmed: 26154083
J Comorb. 2013 Oct 8;3:4-9
pubmed: 29090140
BMJ Open. 2022 Jan 21;12(1):e049133
pubmed: 35063955
J Comorb. 2019 Aug 22;9:2235042X19870934
pubmed: 31489279
Int J Equity Health. 2019 Jul 3;18(1):105
pubmed: 31269953
BMC Med. 2015 Aug 03;13:178
pubmed: 26239481
BMJ Open. 2015 Apr 16;5(4):e007771
pubmed: 25882486
J Am Coll Cardiol. 2019 May 7;73(17):2166-2177
pubmed: 30846341
J Multimorb Comorb. 2022 Jun 16;12:26335565221106074
pubmed: 35734547
Medicine (Baltimore). 2016 Feb;95(7):e2756
pubmed: 26886618
BMC Public Health. 2021 Dec 13;21(1):2275
pubmed: 34903205
J Comorb. 2016 Feb 17;6(1):4-11
pubmed: 29090166
Br J Gen Pract. 2011 Jan;61(582):e12-21
pubmed: 21401985
Pharmacoepidemiol Drug Saf. 2020 Jan;29(1):39-47
pubmed: 31730260
BMC Public Health. 2020 Jul 11;20(1):1094
pubmed: 32652966
J Transcult Nurs. 2022 Sep;33(5):632-641
pubmed: 35583032
Ann Fam Med. 2012 Mar-Apr;10(2):134-41
pubmed: 22412005
J Transcult Nurs. 2022 Jan;33(1):33-40
pubmed: 34318717
J Gerontol A Biol Sci Med Sci. 2019 Apr 23;74(5):659-666
pubmed: 29726918
Health Qual Life Outcomes. 2017 Dec 08;15(1):240
pubmed: 29221456
J Family Med Prim Care. 2021 May;10(5):1823-1828
pubmed: 34195110
Confl Health. 2018 Jul 11;12:33
pubmed: 30008800
PLoS One. 2014 Jul 21;9(7):e102149
pubmed: 25048354
PLoS One. 2017 Apr 6;12(4):e0174322
pubmed: 28384178